论文部分内容阅读
Rituximab is recognized as a useful drug for the treatment of B-cell non-Hodgkin’s lymphoma and its use has been extended to such diseases as idiopathic thrombocytopenic purpura,thrombotic thrombocytopenic purpura,chronic rheumatoid arthritis and ANCA-ass